Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daclizumab in Moderate-to-Severe Ulcerative Colitis
NCT00073047Phase 2Completed
- Sponsor
- Facet Biotech Corporation
- Start
- Apr 2003
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of daclizumab in ulcerative colitis (UC), sponsored by Facet Biotech Corporation. Started Apr 2003; status: completed.
02
Drugs
daclizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00073047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073047.